The critical role of PI3K signalling in normal physiology and its frequent disruption in cancer has led to a major effort in developing inhibitors targeting the key kinase components of this pathway, in particular class I PI3Ks, AKT and mammalian target of rapamycin complex 1/2. The gene discussed is PIK3CD; the disease is cancer.